The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials

European Journal of Cancer

Volumn 75, Issue , 2017, Pages 245-258

  Roviello, Giandomenico ^a,b   Bachelot, Thomas ^c   Hudis, Clifford A ^d,e   Curigliano, Giuseppe ^f   Reynolds, Andrew R ^g   Petrioli, Roberto ^h   Generali, Daniele ^b,i  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c CENTRE LÉON BÉRARD   (France)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ Molecular Therapy and Pharmacogenomics Unit   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Solid tumours

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; MORTALITY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85013851977     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.026     Document Type: Review

References (60)

1. [1] Eskens, F.A., Sleijfer, S., The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer. Where does it fit?. Eur J Cancer 33 (2008), 2350–2356.
2. [2] Rosen, L.S., Ashurst, H.L., Chap, L., Targeting signal transduction pathways in metastatic breast cancer a comprehensive review. Oncologist 15 (2010), 216–235.
3. [3] Linderholm, B., Grankvist, K., Wilking, N., Johansson, M., Tavelin, B., Henriksson, R., Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18 (2000), 1423–1431.
4. [4] Kerbel, R.S., Tumor angiogenesis. N Engl J Med 358 (2008), 2039–2049.
5. [5] Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., Keshet, E., Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1 (1995), 1024–1028.
6. [6] Pañares, R.L., Garcia, A.A., Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 7:4 (2007 Apr), 433–445.
7. [7] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
8. [8] Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
9. [9] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
10. [10] Cochran, W.G., The combination of estimates from different experiments. Biometrics 10 (1954), 101–129.
11. [11] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
12. [12] Aghajanian, C., Blank, S.V., Goff, B.A., Judson, P.L., Teneriello, M.G., Husain, A., et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:17 (2012 Jun 10), 2039–2045.
13. [13] Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:1 (2013 Jan), 29–37.
14. [14] Benson, A.B. 3rd, Kiss, I., Bridgewater, J., Eskens, F.A., Sasse, C., Vossen, S., et al. BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer. Clin Cancer Res 22:20 (2016 Oct 15), 5058–5067.
15. [15] Brufsky, A.M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:32 (2011 Nov 10), 4286–4293 Epub 2011 Oct 11.
16. [16] Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:26 (2011 Dec 29), 2473–2483.
17. [17] Chinot, O.L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:8 (2014 Feb 20), 709–722.
18. [18] Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D.B., et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:11 (2013 Oct), 1077–1085.
19. [19] Spigel, D.R., Townley, P.M., Waterhouse, D.M., Fang, L., Adiguzel, I., Huang, J.E., et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 29:16 (2011 June 1), 2215–2222.
20. [20] Escudier, B., Bellmunt, J., Négrier, S., Bajetta, E., Melichar, B., Bracarda, S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:13 (2010 May 1), 2144–2150.
21. [21] Gianni, L., Romieu, G.H., Lichinitser, M., Serrano, S.V., Mansutti, M., Pivot, X., et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 31:14 (2013 May 10), 1719–1725 Epub 2013 Apr 8.
22. [22] Gilbert, M.R., Dignam, J.J., Armstrong, T.S., Gilbert, M.R., Dignam, J.J., Armstrong, T.S., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:8 (2014 Feb 20), 699–708.
23. [23] Gray, R., Bhattacharya, S., Bowden, C., Miller, K., Comis, R.L., Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:30 (2009 Oct 20), 4966–4972.
24. [24] Guan, Z.Z., Xu, J.M., Luo, R.C., Guan, Z.Z., Xu, J.M., Luo, R.C., et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 30:10 (2011 Oct), 682–689.
25. [25] Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16:13 (2015 Oct), 1355–1369.
26. [26] Hensley, M.L., Miller, A., O'Malley, D.M., Hensley, M.L., Miller, A., O'Malley, D.M., et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 33:10 (2015 Apr 1), 1180–1185.
27. [27] Herbst, R.S., Ansari, R., Bustin, F., Herbst, R.S., Ansari, R., Bustin, F., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377:9780 (2011 May 28), 1846–1854.
28. [28] Hurwitz, H.I., Fehrenbacher, L., Hainsworth, J.D., Heim, W., Berlin, J., Holmgren, E., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:15 (2005 May 20), 3502–3508.
29. [29] Kelly, W.K., Halabi, S., Carducci, M., Kelly, W.K., Halabi, S., Carducci, M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:13 (2012 May 1), 1534–1540.
30. [30] Kindler, H.L., Niedzwiecki, D., Hollis, D., Kindler, H.L., Niedzwiecki, D., Hollis, D., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:22 (2010 Aug 1), 3617–3622.
31. [31] Martín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 33:9 (2015 Mar 20), 1045–1052.
32. [32] Miles, D.W., Chan, A., Dirix, L.Y., Cortés, J., Pivot, X., Tomczak, P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:20 (2010 Jul 10), 3239–3247.
33. [33] Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:26 (2007 Dec 27), 2666–2676.
34. [34] Miller, K.D., Chap, L.I., Holmes, F.A., Miller, K.D., Chap, L.I., Holmes, F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:4 (2005 Feb 1), 792–799.
35. [35] Ohtsu, A., Shah, M.A., Van Cutsem, E., Ohtsu, A., Shah, M.A., Van Cutsem, E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:30 (2011 Oct 20), 3968–3976.
36. [36] Oza, A.M., Cook, A.D., Pfisterer, J., Oza, A.M., Cook, A.D., Pfisterer, J., et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16:8 (2015 Aug), 928–936.
37. [37] Passardi, A., Nanni, O., Tassinari, D., Passardi, A., Nanni, O., Tassinari, D., et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 26:6 (2015 Jun), 1201–1207.
38. [38] Perren, T.J., Swart, A.M., Pfisterer, J., Perren, T.J., Swart, A.M., Pfisterer, J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:26 (2011 Dec 29), 2484–2496.
39. [39] Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:13 (2014 May 1), 1302–1308.
40. [40] Pujol, J.L., Lavole, A., Quoix, E., Pujol, J.L., Lavole, A., Quoix, E., et al., French Cooperative Thoracic Intergroup IFCT. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. Ann Oncol 26 (2015 Feb 16), 908–914.
41. [41] Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21:9 (2010 Sep), 1804–1809.
42. [42] Rini, B.I., Halabi, S., Rosenberg, J.E., Rini, B.I., Halabi, S., Rosenberg, J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:13 (2010 May 1), 2137–2143.
43. [43] Robert, N.J., Diéras, V., Glaspy, J., Brufsky, A.M., Bondarenko, I., Lipatov, O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:10 (2011 Apr 1), 1252–1260.
44. [44] Robert, N.J., Saleh, M.N., Paul, D., Robert, N.J., Saleh, M.N., Paul, D., et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11:2 (2011 Apr), 82–92.
45. [45] Saltz, L.B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 28:12 (2008 April 20), 2013–2019.
46. [46] Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:24 (2006 Dec 14), 2542–2550.
47. [47] Shen, L., Li, J., Xu, J., Pan, H., Dai, G., Qin, S., et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 18:1 (2015 Jan), 168–176.
48. [48] Simkens, L.H., van Tinteren, H., May, A., ten Tije, A.J., Creemers, G.J., Loosveld, O.J., et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385:9980 (2015 May 9), 1843–1852.
49. [49] Stathopoulos, G.P., Batziou, C., Trafalis, D., Koutantos, J., Batzios, S., Stathopoulos, J., et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 78:5-6 (2010), 376–381.
50. [50] Tebbutt, N.C., Wilson, K., Gebski, V.J., Cummins, M.M., Zannino, D., van Hazel, G.A., et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28:19 (2010 Jul 1), 3191–3198.
51. [51] Tewari, K.S., Sill, M.W., Long, H.J. 3rd, Penson, R.T., Huang, H., Ramondetta, L.M., et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:8 (2014 Feb 20), 734–743.
52. [52] Van Cutsem, E., Vervenne, W.L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.L., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:13 (2009 May 1), 2231–2237.
53. [53] von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 15:11 (2014 Oct), 1269–1278.
54. [54] Wick, W., Brandes, A.A., Gorlia, T., Bendszus, M., Sahm, F., Taal, W., et al. EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. J Clin Oncol, 34, 2016 (suppl; abstr 2001).
55. [55] Xie, S., Han, G., Fan, Z., He, L., Xu, W., Qin, Z., Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. Med Oncol, 31(7), 2014 Jul, 35.
56. [56] Zhao, H., Li, X., Chen, D., Cai, J., Fu, Y., Kang, H., et al. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. Med Oncol, 32(2), 2015 Feb, 292.
57. [57] Zhou, C., Wu, Y.L., Chen, G., Liu, X., Zhu, Y., Lu, S., et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 33:19 (2015 Jul 1), 2197–2204.
58. [58] Zinner, R.G., Obasaju, C.K., Spigel, D.R., Weaver, R.W., Beck, J.T., Waterhouse, D.M., et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 10:1 (2015 Jan), 134–142.
59. [59] Delaloge, S., Pérol, D., Brain, E., Asselain, B., Bachelot, T.D., Debledet, M., et al. Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: results of a multicenter national observational study. J Clin Oncol, 34, 2016 (suppl; abstr 1013).
60. [60] Hurwitz, H.I., Saltz, L.B., Van Cutsem, E., Cassidy, J., Wiedemann, J., Sirzén, F., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. JCO 29:13 (2011), 1757–1764.